FGR
Tyrosine-protein kinase Fgr
As of the edition of 20 October 2026, FGR (tyrosine-protein kinase Fgr, UniProt P09769) has 5 drugs tested at it and 6 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09769
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 7
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system; Skin and connective tissue; Lungs and airways; Nervous system; Urinary and reproductive
- Registered trials of its drugs
- 322
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dasatinib anhydrous | Marketed | Phase 4 | Ended 2026 |
| ENMD-981693 | Went quiet | Phase 2 | none listed |
| Ilorasertib | Stopped | Phase 2 | none listed |
| TG100-801 | Stopped | Phase 2 | none listed |
| XL-228 | Stopped | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 2 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Exelixis | Route A |
| CASI pharmaceuticals | Route A |
The other 3 companies at FGR
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at FGR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.